Eli Lilly and Company has entered a worldwide licensing collaboration with France-based Adocia to develop an ultra-rapid insulin, BioChaperone Lispro, to treat people with type 1 and type 2 diabetes.
BioChaperone Lispro will be based on Adocia’s proprietary BioChaperone technology, and is currently in Phase Ib trials. It is being developed to optimise glucose levels during and after meals.
As part of the deal, Lilly will take responsibility for future development, manufacturing and commercialisation of BioChaperone Lispro, which will involve total up-front and milestone payments of $570m.
Lilly Diabetes president Enrique Conterno said: "An ultra-rapid acting insulin, if approved by regulators, could provide a new important treatment option for people with type 1 and type 2 diabetes."
With potential future payments of up to $280m, Adocia will secure a total upfront fee of $50m. It is also provided with an option to receive sales milestones of up to $240m, if the product reaches certain development and regulatory milestones.
Lilly will reimburse Adocia for certain research and development expenses and the BioChaperone Lispro concentrated formulation is also part of the deal, according to Lilly.
The company said the benefits of BioChaperone Lispro include greater flexibility in the timing of insulin injections, lower variability of post-meal blood glucose elevations, lower rates of hypoglycemia and better overall glucose control.
Adocia president Gerard Soula said: "It is a great day for Adocia and Lilly, a global leader in diabetes treatment, to initiate a new collaboration for the development of an innovative ultra-rapid formulation of insulin lispro."
Lilly said that Adocia retains the right to develop and license its insulin programmes unrelated to prandial ultra-rapid insulin.
Image: Eli Lilly headquarters. Photo: courtesy of Guanaco152003.